Advancing Science. Improving Connections.
Next-generation transdermal cannabinoid therapeutics to improve the lives of patients affected by rare and near-rare neuropsychiatric conditions.
Focusing on the unmet medical needs of patients with rare disorders and their families
Progressing our mission to improve the lives of patients battling certain rare and near-rare diseases
Pioneering cannabinoid treatments for neuropsychiatric conditions
Zynerba Pharmaceuticals Announces Publication of Zygel™ (ZYN002) 12-week Open Label Fragile X Syndrome Data in the Journal of Neurodevelopmental DisordersRead More
Zynerba Pharmaceuticals Reports Second Quarter 2019 Financial Results and Operational HighlightsRead More
Zynerba Pharmaceuticals to Present at Two Upcoming ConferencesRead More
Zynerba Pharmaceuticals Added to Russell 2000® and 3000® IndexesRead More